LLY Unusual Options Activity — 2026-04-02

🐋 LLY $5M Bear Put Spread — Institutional Hedge Triggers Day After Historic Oral GLP-1 FDA Approval!

📅 April 2, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

One day after the FDA approved Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) — a landmark moment in the obesity and diabetes drug space — a sophisticated trader just laid down a $5 million bear put spread with 9 months to expiration. They bought the January 2027 $850 puts for $2.8M and simultaneously sold the January 2027 $800 puts for $2.2M, netting a ~$600K debit for the right to collect up to $1.17M if LLY drops ~15% below current levels. With Z-scores of 23.42 and 17.86 (both EXTREMELY_UNUSUAL) and spot at $942.87, this is not a retail trade — it is an institutional hedge or a high-conviction directional bet that Lilly's stock is priced too richly relative to the commercial reality ahead.

---

📊 Company Overview

Eli Lilly and Company (LLY) is the pharma giant at the center of the global obesity and diabetes revolution:

• 💊 What they do: Research-based pharmaceutical company with leading franchises in diabetes (Mounjaro/tirzepatide), obesity (Zepbound), oncology, immunology, and neuroscience
• 💰 Market Cap: ~$850B (one of the five largest companies in the world by market cap)
• 🏢 Sector: Pharmaceuticals
• 📈 Exchange: NYSE
• 📊 Current Price: ~$942.87 (at trade time); GEX snapshot ~$937
• 🌟 Key Story: Just received FDA approval for Foundayo (orforglipron) — the world's first mass-market oral GLP-1 receptor agonist for obesity and type 2 diabetes, a potential $10–20B+ annual revenue drug

---

💰 The Option Flow Breakdown

📊 The Tape

🤓 What This Actually Means

Both legs executed simultaneously at 10:24:29 — this is a single structured trade, a bear put spread:

• 🐻 Strategy: Buy the $850 put + Sell the $800 put (same expiry, same size)
• 💸 Net debit: ~$17.50/share ($77.37 paid − $59.87 received = $17.50 x 100 x 360 contracts = ~$630,000)
• 📉 Maximum profit: $50.00/share (spread width) − $17.50 (net debit) = $32.50/share x 36,000 shares = $1.17M (if LLY closes below $800 at January 2027 expiration)
• 🎯 Breakeven: $850 − $17.50 = $832.50 (LLY must fall ~11.7% from $942.87)
• 📊 Max loss: $17.50/share x 36,000 = ~$630,000 (net debit paid if LLY stays above $850)
• 🔢 Risk/Reward: ~1.86:1 max profit vs max loss
• ⏰ 9 months to expiration (January 15, 2027) — a LEAPS-style hedge
• 📊 Vol/OI ratio: $850 leg = 1.65x (HIGH_ACTIVITY, new open), $800 leg = 0.508x (adds to existing OI of 711)
• 🎯 Z-scores: 23.42 (EXTREMELY_UNUSUAL) and 17.86 (EXTREMELY_UNUSUAL) — both well above the threshold for institutional attention
• 🤝 MID fills on both legs — hallmark of institutional block negotiation, not retail market orders

What's the thesis here?

This trader is NOT bullish on one of the biggest pharma stories in history. The day after a landmark FDA approval, they are buying downside protection — 9 months out, with strikes 10–16% below the current price. This structure has three possible interpretations:

1. Portfolio hedge: A large LLY long-holder is buying insurance against a "sell the news" reversal after Foundayo's approval. They are capping downside at $800 on a 9-month horizon.
2. Directional bearish bet: Conviction that commercialization challenges, pricing disputes, manufacturing scale-up issues, or broader market rotation will push LLY meaningfully lower by January 2027.
3. Valuation hedge: At ~$850B market cap, LLY is priced for near-perfect GLP-1 execution. A single setback — rebate pressure, formulary access, competitive entry, or political drug-pricing action — could reprice the stock rapidly.

The simultaneous MID execution, identical 360-contract sizes, and both legs classified as OPEN (new positions) confirm this is a freshly structured spread, not an unwind.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

LLY has been on a multi-year GLP-1 driven tear, but 2026 has brought volatility:

• 🚀 Long-term run: LLY has been one of the best-performing large-cap stocks of the past 3 years, driven by Mounjaro and Zepbound's explosive commercial ramps
• 📊 Current level ~$942: Reflects the market's expectation of sustained GLP-1 franchise growth, oral drug optionality, and pipeline depth
• 📅 April 1 FDA approval of Foundayo: Creates an immediate "buy the rumor, sell the news" dynamic — the stock may have already priced in oral GLP-1 approval
• 🎢 Elevated implied volatility: 25.8% implied move over 12 months per the options market signals persistent uncertainty around commercialization execution
• 🛡️ Options market implied range by Jan 2027 OPEX: $726.80 (lower) to $1,147.58 (upper) — the $800 and $850 put strikes both sit within the implied lower range, validating these strikes as relevant downside scenarios

Gamma-Based Support & Resistance Analysis

Current Price: $937.27 (GEX snapshot at 14:17 ET)

The gamma exposure map shows where options market makers have concentrated positions, creating natural price magnets and barriers:

🔵 Support Levels (Put Gamma Below Price):

• $935 — Nearest support, tight floor with balanced GEX (just 0.24% below spot)
• $930 — Near-term structural support with bullish net GEX
• $920 — Net negative GEX (puts dominant) — first level where dealer hedging accelerates downside
• $910 — Significant put concentration with -0.888B net GEX (dealers short gamma below here)
• $900 — The psychological and gamma anchor: 2.43B total GEX, -1.36B net. This is the LINE IN THE SAND for near-term technical support

🟠 Resistance Levels (Call Gamma Above Price):

• $940 — Immediate resistance, strongest total GEX cluster at 3.74B. This is the first ceiling just 0.3% above current price
• $950 — Major resistance at 3.49B total GEX with 2.14B net call GEX — dealers will sell into rallies here
• $1,000 — Extended resistance; psychological round number with 2.62B total GEX

What this means for traders:

LLY is trading in a very tight gamma sandwich: strong immediate resistance at $940 just 0.3% overhead, and nearest support at $935 just 0.24% below. The stock is coiled between these levels. A break above $950 with conviction opens $960, but the $940-$950 zone is a thick call gamma wall that will require significant buying pressure to clear.

Conversely, a break below $930 (where net GEX flips to put-dominant territory) could accelerate toward $900 — the major structural gamma support. The bear put spread is designed to profit precisely in this scenario: if $900 gives way, the $850 target becomes the next gravitational level.

Net GEX Bias: Bullish (25.5B total call GEX vs 22.2B total put GEX) — overall dealer positioning leans modestly bullish, suggesting the market-maker community will defend the current range near-term. However, the put-dominant net GEX below $920 means any break lower will be self-reinforcing.

Implied Move Analysis

Options market pricing for upcoming expirations:

Translation:

By the time this trade expires on January 15, 2027, the options market says LLY could be anywhere from $726.80 to $1,147.58. That is an enormous range reflecting both the transformative upside from GLP-1 franchise dominance and the very real downside from pricing, competition, and execution risk.

Key insight for this trade:

• The $850 breakeven is within the implied distribution (below the $890.82 lower OPEX range for April but closer to the June-September lower ranges)
• The $800 max-profit level is above the yearly LEAPS lower range of $726.80 — meaning the market says there is a non-trivial probability LLY goes below $800
• The September 2026 Triple Witch lower range of $797.18 passes through the short put strike — the market's own implied move says the $800 level could be tested as early as September
• At the January 2027 OPEX, the lower bound of $726.80 suggests the market is pricing meaningful downside well below both put strikes

---

🎪 Catalysts

🔥 Upcoming Catalysts

Q1 2026 Earnings — Expected Late April / Early May 2026 📊

LLY's next major financial checkpoint. Key metrics to watch:

• 💊 Mounjaro (tirzepatide, diabetes) quarterly sales trajectory — must sustain >$4B quarterly pace
• 🏃 Zepbound (tirzepatide, obesity) demand vs manufacturing capacity — access remains the key constraint
• 🗣️ First commercial commentary on Foundayo (orforglipron) — FDA just approved it; management will guide on launch timing, pricing strategy, and patient access
• 📉 Gross margin trends as manufacturing scale-up investments continue
• 🌍 International GLP-1 access — EU approvals, pricing negotiations, ex-US commercialization build-out
• 📊 Any updates on donanemab (Alzheimer's) commercial trajectory

Foundayo (Orforglipron) Commercial Launch — Q2/Q3 2026 💊

This is THE make-or-break catalyst for LLY's valuation premium. The world's first oral GLP-1 receptor agonist for obesity and type 2 diabetes was approved by the FDA on April 1, 2026. Key dynamics:

• 🏆 First-mover advantage: No competing oral GLP-1 approved yet — clear market leadership if launch execution is strong
• 💰 Pricing and reimbursement: PBM formulary access negotiations will determine volume. Injectable Zepbound faces reimbursement headwinds; oral pill could face similar battles
• 🏭 Manufacturing: Small-molecule pill manufacturing is theoretically more scalable than injectable biologics — production capacity less likely to be the bottleneck vs Mounjaro/Zepbound
• 📊 Clinical data: Phase 3 ACHIEVE trials showed ~8% weight loss at 36 weeks for orforglipron vs ~15-20% for injectable tirzepatide — a real efficacy gap vs Zepbound that could limit substitution
• 🤝 Addressable market: 100M+ Americans with obesity or type 2 diabetes who cannot/will not inject — oral route dramatically expands accessible market
• ⚔️ Competition watch: Pfizer's oral GLP-1 (danuglipron) is in Phase 3; Viking Therapeutics oral candidate in development; Novo Nordisk's oral semaglutide (Rybelsus) already on market but at lower doses

Q2 2026 Earnings — Expected Late July/Early August 2026 📊

• First full quarter reflecting Foundayo launch momentum
• Zepbound/Mounjaro quarterly trajectory as competition intensifies
• Manufacturing capacity updates — $9B+ capex program progress
• Donanemab (Kisunla) Alzheimer's drug commercial update — early launch phase

Alzheimer's Drug Kisunla (Donanemab) — Ongoing Commercial Ramp 🧠

Donanemab received FDA approval for Alzheimer's disease in July 2024 under the brand name Kisunla:

• 📊 Competing directly with Biogen/Eisai's Leqembi in a nascent but potentially massive market
• 💰 Annual list price ~$32,000 — significant but faces reimbursement barriers
• 🏥 Requires PET scans and infusion center infrastructure — limits near-term uptake
• 📈 Long-term Alzheimer's market could be $10–15B annually by 2030 if diagnosis and treatment infrastructure scales

2026 PDUFA Dates & Pipeline Milestones 📋

• Pirtobrutinib (Jaypirca) label expansions in CLL/NHL — growing oncology franchise
• Lebrikizumab (Ebglyss) atopic dermatitis — expanding into competitive IL-13 inhibitor market
• Next-gen obesity pipeline: Retatrutide (GLP-1/GIP/glucagon tri-agonist) and orforglipron label expansion potential — addressing weight regain and combination therapy space
• Tirzepatide SURMOUNT-5 data — head-to-head vs semaglutide for obesity weight loss; data publication could create significant narrative swing

Drug Pricing / IRA Negotiation Risk — Ongoing Political Catalyst ⚖️

The Inflation Reduction Act's Medicare drug price negotiation program is actively targeting high-revenue drugs. Tirzepatide's GLP-1 dominance makes it a prime eventual target for price negotiation. Any adverse pricing headlines or political proposals could reprice LLY's earnings multiple quickly.

✅ Recent Catalysts (Already Happened)

FDA Approval of Foundayo (Orforglipron) — April 1, 2026 (YESTERDAY!) 💊

The single most significant recent event for LLY's long-term trajectory. The FDA approved orforglipron (brand name Foundayo) for:

• Type 2 diabetes management
• Obesity/overweight with at least one weight-related condition

This is the world's first once-daily oral GLP-1 receptor agonist approved for both indications simultaneously. The market's initial reaction was positive (stock at $942.87 at trade time), but the bear put spread suggests at least one institutional player believes the approval was a "sell the news" moment — the stock may have already priced in oral GLP-1 success.

Q4 2025 Earnings Results 📊

LLY reported strong Q4 2025 results with continued GLP-1 franchise momentum:

• Mounjaro and Zepbound combined sales remain the core revenue driver
• Manufacturing investments continue to weigh on near-term margins
• Full-year 2026 guidance reflects sustained but moderating growth vs the hypergrowth of 2023-2025

Zepbound Medicare Coverage Expansion 🏥

CMS coverage decisions expanding GLP-1 access for obesity in Medicare beneficiaries represent a multi-year tailwind — but also create reimbursement/rebate pressures that compress effective net pricing.

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, catalyst calendar, and the bear put spread structure, here are the scenarios through the January 15, 2027 expiration:

📈 Bull Case (40% probability) — Spread Loses Max

Target: $950–$1,100+

How we get there:

• 🚀 Foundayo launch exceeds expectations — PBM formulary access secured quickly, strong prescription volume in first 90 days
• 💊 Mounjaro/Zepbound maintain market leadership despite competitive entry — combined $18B+ annual run rate
• 🧠 Kisunla Alzheimer's drug begins meaningful commercial ramp
• 📊 Q1 and Q2 earnings beat consensus — management raises full-year guidance
• ⚔️ Competition less disruptive than feared: Pfizer's danuglipron faces delays or safety issues
• 🌍 EU approval and reimbursement deals for Foundayo expand global opportunity
• 📈 Stock breaks through $940/$950 gamma resistance, targeting $1,000 round number

Spread trade P&L at $950+: Both puts expire worthless → maximum loss of ~$630K (-100% of net debit) Note: Maximum loss on the spread is the net premium paid — the downside is strictly defined

🎯 Base Case (35% probability) — Spread Partially Profits

Target: $832–$940 range

Most likely scenario:

• ✅ Foundayo launch progresses but faces formulary hurdles — slower ramp than bulls hope
• 📊 Mounjaro/Zepbound growth continues but decelerates as competition intensifies
• ⚖️ Market gradually reprices GLP-1 premium as IRA drug pricing risk becomes more concrete
• 📉 Stock drifts lower through the $900 GEX support level toward the $850–$880 range
• 🔄 Broader pharma sector rotation as biotech/early-stage competes for capital

Spread P&L at $870 (between strikes): $850 put worth ~$20, $800 put ~$0 → partial profit ~$250K–$350K Spread P&L at $835 (near breakeven): $850 put worth ~$15, $800 put ~$0 → near breakeven Spread P&L at $800 (at max): $850 put worth $50, $800 put worth $0 → maximum profit $1.17M

📉 Bear Case (25% probability) — Spread at Maximum Profit

Target: $700–$832

What could go wrong for LLY bulls:

• 😰 Foundayo commercial disappointment: Formulary rejection from major PBMs, or efficacy narrative pressure (8% vs 15%+ for injectable tirzepatide hurts perception)
• 💊 Competitive disintermediation: Pfizer danuglipron approval or Viking Therapeutics oral candidate success compresses LLY's premium
• 💰 IRA Medicare pricing: Tirzepatide named in next negotiation cycle — any confirmation crushes earnings estimates
• 📉 Manufacturing shortfalls: Continued supply constraints for injectables offset by oral, but miss on guidance
• 🏥 Payer pushback: PBMs require significant rebates to maintain formulary position across both injectable and oral GLP-1s — net pricing erodes
• 📊 Macro rotation: Rate-sensitive, high-multiple pharma names sell off in risk-off or healthcare regulatory uncertainty environment
• ⚖️ Political risk: Drug pricing legislation risk intensifies ahead of 2026 midterms
• 🧠 Kisunla disappoints: Alzheimer's commercial ramp slower than forecasted, removing a key earnings growth pillar

Spread P&L at $800 or below: Both puts settle in-the-money at spread maximum → profit = $1.17M (+186% ROI on net debit) Spread P&L at $750: Same max profit — the short $800 put is also ITM but the spread value caps at $50/share

---

💡 Trading Ideas

🛡️ Conservative: "Follow the Hedge" — Defined-Risk Put Spread (Smaller Size)

Play: Replicate the institutional structure at retail scale — buy the LLY January 2027 $850 put, sell the LLY January 2027 $800 put

Structure: Same $850/$800 bear put spread, January 15, 2027 expiration

Why this works:

• 🐻 Directly mirrors the institutional positioning — if a sophisticated player sized $5M into this spread, the structure is the correct risk expression for a bearish view
• 🛡️ Strictly defined risk: maximum loss is net debit paid (~$17.50/spread) — no margin calls, no unlimited loss
• 💰 Max profit if LLY below $800 at expiry: $32.50/spread vs ~$17.50 cost = ~1.86:1 gross reward/risk
• ⏰ 9-month duration captures all major catalysts: Q1/Q2 earnings, Foundayo launch trajectory, competitive data releases, IRA negotiation announcements
• 📊 The $900 gamma support level is a natural early-warning indicator — a break below $900 signals the thesis is developing

Position sizing: Risk no more than 2–3% of portfolio. 5 spreads at ~$1,750 net debit each = ~$8,750 at risk for ~$16,250 max profit.

Risk level: Moderate (defined risk, directional) | Skill level: Intermediate

⚖️ Balanced: "Sell the News" — Near-Term Calendar Spread

Play: Buy the LLY June 2026 $900 put, sell the LLY April 17 $900 put (put calendar spread)

Why this works:

• 📅 Captures near-term "sell the news" dynamics following FDA approval — IV crush on April OPEX creates a cheaper long put entry
• 💸 Net debit significantly lower than outright long puts — the short front-month put funds time value
• 📊 April OPEX implied range of $890.82–$983.56 puts $900 right at the lower bound — high probability the short put expires worthless
• 📈 If LLY drifts toward $900 over the next 2–6 weeks, the calendar spreads appreciates significantly
• ⏰ Can roll repeatedly: sell each month's $900 put to finance the longer-dated put, laddering into the bear thesis

Position sizing: 5–10 calendars — relatively capital-efficient structure.

Risk level: Moderate (requires active management) | Skill level: Intermediate-Advanced

🚀 Aggressive: "Conviction Bearish" — Outright Long Puts

Play: Buy LLY September or October 2026 $880 or $900 puts outright

Why this works (and why it's risky):

• 🎯 Higher delta (more responsive to immediate price decline) vs the spread
• 📅 September Triple Witch lower implied range of $797 gives a reasonable catalyst timeline
• 💰 No short put to cap upside: if LLY drops to $800 or below, outright puts have unlimited downside leverage
• 📊 A break below $900 GEX support could cascade rapidly toward $870–$850 given the put-dominant gamma profile below $920

Why it could blow up:

• 💸 Full premium at risk (~$40–60/contract for September $880 puts) — expensive decay
• 📈 If Foundayo launch is strong, LLY rallies through $950 and puts lose 50%+ rapidly
• ⏰ Theta decay is relentless on outright long puts — need the move to happen soon
• 🎢 LLY has consistently squeezed bears — the stock has powerful buyback and institutional bid support

Position sizing: Risk ONLY what you can afford to lose completely. 5 contracts = ~$25,000–$30,000 at risk.

Risk level: HIGH (can lose 100% of premium) | Skill level: Advanced

---

⚠️ Risk Factors

Don't get caught by these potential landmines:

• 🚀 "Sell the news" setup, but what if it's "buy the news" after all? Foundayo approval is genuinely transformative. If early prescription data is strong and PBM access is secured faster than feared, LLY could break through $950-$1,000 quickly. The bear spread's $850 breakeven requires an 11.7% decline from current levels — the stock needs to give back significant post-approval gains.

• 📊 GEX shows a bullish bias: Total call GEX (25.5B) exceeds total put GEX (22.2B), meaning dealers are net short gamma in calls. In a rising market, they must buy stock to hedge — creating a self-reinforcing upward squeeze. The immediate $940 resistance with 3.74B total GEX is a wall, but a strong catalyst breaks gamma walls.

• 💊 Oral GLP-1 efficacy narrative could run hot: At 8% weight loss vs 15-20% for injectable Zepbound, orforglipron looks inferior clinically. But the addressable market expands by an order of magnitude with a pill (needle-phobic patients, primary care prescribing vs specialist, global markets with cold chain limitations). If "oral" outweighs "less effective" in prescriber/patient perception, volume could overwhelm the efficacy discount narrative.

• ⚔️ No credible oral GLP-1 competitor until 2027: Pfizer's danuglipron and Viking's oral candidate are still in late-stage trials. LLY has potentially 12–24 months of oral GLP-1 market exclusivity. First-mover advantage in drugs with strong network effects (patient support programs, provider familiarity) is enormously valuable.

• 🏥 Medicare GLP-1 obesity coverage expansion: CMS has been expanding GLP-1 coverage for Medicare beneficiaries — an enormous patient population. If coverage is confirmed and access broadens, Foundayo could be the catalyst for volume acceleration across LLY's GLP-1 franchise.

• 💰 LLY's balance sheet and capital return: Lilly generates massive free cash flow from tirzepatide. Share buybacks and dividend growth provide a floor bid on the stock, limiting severe downside absent a major negative catalyst.

• 🌍 Manufacturing investments accelerating: LLY's $9B+ capital expenditure program to build out GLP-1 manufacturing capacity has weighed on margins. As that capacity comes online through 2026-2027, margin expansion could be a positive earnings surprise catalyst — bullish for the stock and adverse for the bear spread.

• 📅 January 2027 OPEX timing risk: Expiring on January 15, 2027 means the trade misses any post-January 2027 catalysts. If the bear thesis is correct but plays out in Q1 2027, the spread expires worthless even though the directional thesis proved right.

---

🎯 The Bottom Line

Here's the deal: The very day after Eli Lilly got arguably the most important FDA approval in its history — the first oral GLP-1 for obesity — a sophisticated institutional player spent $5 million to structure a 9-month bear put spread targeting a 10–16% decline in the stock. This is not a casual trade. The 23.42 and 17.86 Z-scores on both legs are EXTREMELY_UNUSUAL, marking this as among the most statistically anomalous options activity you will see in large-cap pharma.

What this trade tells us:

• 🐻 At least one major player believes LLY is priced for perfection and the approval is a "sell the news" event, not a "buy the news" event
• 💰 The bear put spread structure (not naked puts) signals sophistication — they want defined risk, not unlimited exposure, suggesting this is a hedge alongside a large LLY long position OR a high-conviction position-sized directional play
• 📊 The $850/$800 strikes align with what the implied move analysis says is a realistic 9-month downside range (Jan 2027 lower bound: $726.80) — these are not crazy strikes
• ⚙️ The net debit of ~$630K vs maximum profit of ~$1.17M (1.86:1 gross reward/risk) is an efficient, capital-conscious structure — consistent with a risk-management overlay rather than pure speculation
• 🔢 Both legs classified as fresh OPEN positions (high Vol/OI on the $850 leg at 1.65x) confirms new money, new conviction

This IS a bearish signal, but with critical context:

Lilly is not a broken company. The GLP-1 franchise remains the most commercially successful pharmaceutical franchise launch in history. The oral GLP-1 approval expands the addressable market dramatically. The bear thesis requires either commercial execution disappointment, pricing/reimbursement setbacks, competitive disruption, or a macro-driven multiple compression — none of which are base-case outcomes.

If you're bearish on LLY:

• ✅ Mirror the institutional spread structure (defined-risk bear put spread) rather than naked puts — the max-loss is known and controlled
• 📊 Watch the $900 GEX support level as your primary early-warning signal — a sustained close below $900 confirms dealers will add downside momentum
• ⏰ Mark Q1 earnings (late April/early May) as the first major checkpoint — Foundayo prescription data and Q1 guidance will define the next 3-6 months of direction
• 🏥 Monitor PBM formulary decisions in the first 60-90 days post-approval — this is the single most important commercial variable

If you're bullish on LLY:

• 🎯 The $940 resistance wall is your near-term battleground — a decisive break above $950 with strong Foundayo prescription data could unlock $1,000
• 📊 The $935 GEX support just 0.24% below is a very tight floor — a break below $930 changes the short-term technical picture
• 💊 Track early pharmacy fill data and any commercial partners announcements — patient demand signals will emerge within weeks
• 📈 Analyst targets likely to be revised upward if Q1 Foundayo launch metrics surprise positively

If you're cautious:

• 🎯 Wait for post-earnings clarity before committing large capital in either direction
• 📉 The $900 gamma support level is where you want to buy the dip IF it holds — that's a 4% discount from current levels with major structural support
• ⚠️ Options market is pricing 4.95% near-term move through April 17 OPEX — the stock could be at $985 or $891 within 15 days. Size accordingly.

Key dates to mark:

• 📅 April 17, 2026 — April OPEX (15 days away; market pricing ±4.95% move = $890–$984 range)
• 📅 Late April/Early May 2026 (estimated) — Q1 2026 Earnings (first post-Foundayo-approval guidance)
• 📅 Q2/Q3 2026 — Foundayo commercial launch and early prescription data
• 📅 June 19, 2026 — Triple Witch OPEX (implied lower range: $848.36 — approaches bear spread $850 breakeven)
• 📅 July/August 2026 — Q2 2026 Earnings (first full Foundayo launch quarter)
• 📅 September 18, 2026 — Triple Witch OPEX (implied lower range: $797.18 — right at the $800 short put strike)
• 📅 Late 2026 — IRA drug pricing negotiation cycle updates (tirzepatide risk)
• 📅 January 15, 2027 — THIS TRADE EXPIRES — moment of truth for the $5M bear spread

Final verdict: Someone with deep institutional knowledge of LLY's commercial pipeline just laid down a precisely structured, statistically extreme hedge against the day after one of pharma's biggest FDA approvals. That is not noise. It is a clear signal that at $942, the risk/reward for LLY is not as obviously bullish as the headlines suggest. The oral GLP-1 market is transformative — but it is also fiercely contested, reimbursement-sensitive, and dependent on execution against a backdrop of political drug pricing pressure. The smarter approach here is defined-risk structures on both sides: if you are bullish, use call spreads to limit your premium burn; if bearish, mirror this institutional bear put spread to cap your loss while preserving full profit potential below $800.

Watch the $900 level. It is the pivot. Below it, gamma accelerates the decline. Above it, the bull remains in control. And remember: whoever bought $5 million worth of downside protection the day Foundayo was approved — they know something about how this story ends, or they are very well-paid to worry about the scenarios no one wants to think about. 🐻

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance does not guarantee future results. Bear put spreads involve complex risk considerations including time decay, volatility changes, and liquidity risk. Maximum loss on a debit spread is the net premium paid; however, the position may lose significant value before expiration. Always do your own research and consider consulting a licensed financial advisor before trading.

---

About Eli Lilly and Company: Eli Lilly and Company is a research-based pharmaceutical company with leading franchises in diabetes (Mounjaro/tirzepatide), obesity (Zepbound), oncology, immunology, and neuroscience. The company is the developer and marketer of Foundayo (orforglipron), the world's first FDA-approved oral GLP-1 receptor agonist for obesity and type 2 diabetes, with a market cap of approximately $850B.